Health Care

Snapshot of Analyst’s Forecasts: Halozyme Therapeutics, Inc. (NASDAQ:HALO)

0 5

Halozyme Therapeutics, Inc. (NASDAQ:HALO) closed its last session at $11.05 with the change of +2.70%. The market capitalization of the company is $1.41B with an average Volume of 1.23 million shares. The stock currently has its 52-Week High range of $19.63 and 52-week low range of $6.96. The Price to Book (P/B) ratio stands at 137.95. The stock traded total quantity of 1.4 million shares.

Currently Halozyme Therapeutics, Inc. (HALO) captured an average recommendation of “ Overweight ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “7″ Analysts”. “1” rated “Sell” for the company. “0” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.

Analysts are expecting that the company to achieve $14.54 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $20.00 however minimum price target advised by analysts is $6.75. The Median price target for the stock is measured at $16.00.

Presently, Analysts decided consensus EPS estimate of $-0.26 for present quarter and one month ago projected EPS estimate was at $-0.27. If we take a look at back 3 month ago, consensus EPS estimate was $-0.30.

A current consensus EPS estimate for next quarter is at $-0.29 and 3 month ago EPS forecast was $-0.30. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.29.

For current fiscal year, most recent EPS estimate is set at $-0.91 based on Analyst consensus and three month ago consensus EPS opinions was at $-1.03. During period one month ago, consensus EPS forecast was decided at $-0.92.

A current consensus EPS projection for next fiscal year is observed at $-0.83 and one month ago consensus EPS forecast was at $-0.78. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-0.80 by analysts.

One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 7 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 0 advised the “Hold” rating about this stock. 1 revealed “Sell” signal and “Underweight” rating was declared by 0.

Three Months Ago, Analysts recommended an average brokerage rating of Overweight derived from brokerage firms, according to FactSet. 7 said a “Buy Rating” and 0 announced “Overweight Rating”. 0 advised “Hold Rating” regarding the stock. 1 announced “Sell Rating” and 0 disclosed “Underweight Rating”.

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.